Clinical Commander

Back to dossier
cardio.atrial_flutter.post-pvi-iatrogenic.v1PRODUCTION
cardio.atrial_flutter.post-pvi-iatrogenic.v1

Iatrogenic post-PVI atypical LA flutter (gap-related macroreentry)

cardiologyacutechronicadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Iatrogenic atypical flutter from gap-related macroreentry 1-12 mo post-PVI (post-blanking window per HRS 2017). Three dominant circuits: mitral-isthmus, LA roof, perimitral. Redo ablation with gap targeting + linear lesion completion is definitive — Calkins 2017 (PMID 28506916)

Inputs
2
Actions
0
Advance rule
Set
Advance when

Post-PVI substrate + atypical morphology confirmed

Patient inputs (12)

CHA2DS2-VASc + redo ablation candidacy + life expectancy for risk-benefit

Conduction ratio variable (1:1, 2:1, 3:1) — atypical post-PVI flutter often has slower flutter rates (200-260 bpm) than typical CTI (250-300) due to large reentrant circuit length

Anchors substrate; lesion set (PVI alone vs PVI + roof line vs PVI + mitral isthmus) directly predicts circuit type — Chae 2007 (PMID 17698994)

Atypical morphology — mitral-isthmus flutter often positive in II/III/aVF + isoelectric/notched in V1 OR roof-dependent flutter has variable polarity; CRITICAL discriminator from sinus rhythm at slower rates — Patel 2008 (PMID 18272844)

DOAC + AAD dosing; contrast for redo 3D mapping/ablation

Reversible cause screen; amiodarone-induced thyroid dysfunction common from post-PVI bridging amio

LA size + EF + valvular function + post-ablation pericardial effusion screen; mitral annulus assessment for mitral-isthmus circuit

SBP <90 with iatrogenic flutter RVR → emergent DCCV 100-200 J biphasic (atypical may need higher energy than typical)

AC indication identical to AF; lifelong typical post-PVI given mixed AF/AFL substrate

HAS-BLED + redo-ablation peri-procedure bleed risk

Prior PV reconnection on imaging/EP follow-up identifies gap location; informs redo strategy

LA appendage thrombus exclusion + chamber anatomy + PV ostia for 3D mapping at redo — required if AC <3 wk uninterrupted (HRS 2017 PMID 28506916)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningunstable_post_pvi_flutter_requires_emergent_dccv
    Iatrogenic post-PVI atypical flutter with SBP <90, AMS, ongoing ischemia, or pulmonary edema → synchronized DCCV 100-200 J biphasic now (atypical may need higher energy than typical CTI)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpost_la_redo_atrioesophageal_fistula_warning
    Fever + chest pain + new neurologic deficit 2-6 weeks post-LA redo (mitral isthmus line) → emergency surgical evaluation; HIGHER RISK than CTI
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereanticoag_continuity_during_redo_ablation
    Periprocedural AC management for redo LA ablation — uninterrupted DOAC vs interrupted with bridge; RE-CIRCUIT and VENTURE-AF support uninterrupted
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereamiodarone_toxicity_in_post_pvi_bridge
    New pulmonary infiltrates, thyroid dysfunction (hypo or hyper), or LFT elevation on amiodarone bridge — switch AAD or accept AAD failure → expedite redo ablation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepost_pvi_recurrence_within_blanking_window
    Recurrent atrial arrhythmia within 1-3 month blanking window post-PVI — common, may not represent true failure; 3-12 mo recurrence = true failure requiring redo ablation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatemixed_af_aflutter_conversion_post_pvi
    Conversion from post-PVI atypical AFL to AF (or AF to AFL) during post-PVI surveillance — mixed substrate present (rule rather than exception)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Iatrogenic post-PVI atypical LA flutter — rate control + AAD bridge + AC + REDO 3D electroanatomic mapping ablation pathway with gap targeting + linear lesion completion — ACC/AHA 2024 (Joglar PMID 38753446); HRS 2017 (Calkins PMID 28506916)
axis: post_pvi_atypical_flutter_redo_ablation_pathway
Selected axis "Iatrogenic post-PVI atypical LA flutter — rate control + AAD bridge + AC + REDO 3D electroanatomic mapping ablation pathway with gap targeting + linear lesion completion — ACC/AHA 2024 (Joglar PMID 38753446); HRS 2017 (Calkins PMID 28506916)" by default fallback (first axis)
  • metoprolol_tartrate
    first line
    beta_blocker
    5 mg IV q5min × 3 then 25-50 mg PO BID • IV/PO • IV q5min × 3 → PO BID
    triggers: post_pvi_atypical_flutter_with_RVR, no_HFrEF_decompensation
    AVN slowing for post-PVI flutter — ACC/AHA 2024 (PMID 38753446)
    rxcui 203191
  • metoprolol_succinate
    first line
    beta_blocker
    25-50 mg PO daily; titrate • PO • daily
    triggers: chronic_rate_control_bridge_to_redo_ablation
    Long-acting BB bridge to redo ablation — ACC/AHA 2024
    rxcui 866427
  • amiodarone
    first line
    class_III_AAD
    150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance • IV/PO • load + daily
    triggers: post_pvi_atypical_flutter, structural_heart_disease, HFrEF, gap_related_substrate
    Most efficacious AAD bridge to redo ablation; preferred over class IC (CAST PMID 1900101) given post-PVI scar substrate; pulm/thyroid/hepatic toxicity monitoring — ACC/AHA 2024 (PMID 38753446)
    rxcui 703
  • dofetilide
    second line
    class_III_AAD
    125-500 mcg PO BID per CrCl (REMS — inpatient initiation) • PO • BID
    triggers: amiodarone_toxicity_or_intolerance, rhythm_maintenance, baseline_QTc_<440
    Alternative to amiodarone; dofetilide REMS — must be initiated inpatient with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446)
    rxcui 49247
  • apixaban
    first line
    DOAC_factor_Xa
    5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) • PO • BID
    triggers: CHA2DS2VASc_>=2_men_>=3_women, pre_post_cardioversion, pre_post_redo_ablation, mixed_AF_AFL_post_PVI
    AC same as AF; lifelong AC typical post-PVI given high mixed AF/AFL coexistence — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978)
    rxcui 1364430
  • rivaroxaban
    second line
    DOAC_factor_Xa
    20 mg with food (15 mg if CrCl 15-50) • PO • once daily
    triggers: apixaban_unavailable, continuous_DOAC_during_redo_per_VENTURE_AF
    X-VeRT (PMID 24837375); VENTURE-AF (PMID 25975659) supports uninterrupted rivaroxaban during ablation
    rxcui 1114195
  • dabigatran
    second line
    DOAC_direct_thrombin
    150 mg BID (110 mg BID if age ≥75 or CrCl 30-50 in EU labelling) • PO • BID
    triggers: continuous_DOAC_during_redo_per_RE_CIRCUIT
    RE-CIRCUIT (PMID 28530171) — uninterrupted dabigatran non-inferior to interrupted during AF ablation
    rxcui 1037045
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    INR 2-3 • PO • daily
    triggers: mechanical_valve, severe_mitral_stenosis, DOAC_contraindicated
    Mechanical valve / severe MS — only warfarin — ACC/AHA 2024
    rxcui 11289

outpatient playbook — drug actions (2)

  1. 1. continue DOAC lifelong if CHA2DS2-VASc ≥2 or mixed AF/AFL
    rxcui 1364430
    apixaban 5 mg BID per CHA2DS2-VASc • PO • BID
    trigger: Persistent stroke risk OR mixed AF/AFL post-PVI
    Lifelong AC — ACC/AHA 2024 Class I
  2. 2. continue amiodarone if redo incomplete
    rxcui 703
    200 mg PO daily • PO • daily
    trigger: AAD-dependent rhythm maintenance
    Lower recurrence than other AAD — ACC/AHA 2024

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Atrial arrhythmia recurrence 1-12 months after PVI for AF — post-blanking-period (HRS 2017 PMID 28506916) early recurrence window; ECG atypical flutter morphology (positive II/III/aVF, prominent V1, mitral-isthmus or roof-circuit pattern) in patient with prior PVI; Palpitations / dyspnea / fatigue / reduced exercise tolerance after recent (1-12 mo) PVI for AF.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Iatrogenic post-PVI atypical LA flutter (gap-related macroreentry)** (cardio.atrial_flutter.post-pvi-iatrogenic.v1).
Scope: Iatrogenic atypical flutter from gap-related macroreentry 1-12 mo post-PVI (post-blanking window per HRS 2017). Three dominant circuits: mitral-isthmus, LA roof, perimitral. Redo ablation with gap targeting + linear lesion completion is definitive — Calkins 2017 (PMID 28506916)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Iatrogenic post-PVI atypical LA flutter — rate control + AAD bridge + AC + REDO 3D electroanatomic mapping ablation pathway with gap targeting + linear lesion completion — ACC/AHA 2024 (Joglar PMID 38753446); HRS 2017 (Calkins PMID 28506916)**.
1. metoprolol_tartrate 5 mg IV q5min × 3 then 25-50 mg PO BID IV/PO IV q5min × 3 → PO BID (beta_blocker, first line) — AVN slowing for post-PVI flutter — ACC/AHA 2024 (PMID 38753446)
2. metoprolol_succinate 25-50 mg PO daily; titrate PO daily (beta_blocker, first line) — Long-acting BB bridge to redo ablation — ACC/AHA 2024
3. amiodarone 150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance IV/PO load + daily (class_III_AAD, first line) — Most efficacious AAD bridge to redo ablation; preferred over class IC (CAST PMID 1900101) given post-PVI scar substrate; pulm/thyroid/hepatic toxicity monitoring — ACC/AHA 2024 (PMID 38753446)
4. dofetilide 125-500 mcg PO BID per CrCl (REMS — inpatient initiation) PO BID (class_III_AAD, second line) — Alternative to amiodarone; dofetilide REMS — must be initiated inpatient with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446)
5. apixaban 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) PO BID (DOAC_factor_Xa, first line) — AC same as AF; lifelong AC typical post-PVI given high mixed AF/AFL coexistence — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978)
6. rivaroxaban 20 mg with food (15 mg if CrCl 15-50) PO once daily (DOAC_factor_Xa, second line) — X-VeRT (PMID 24837375); VENTURE-AF (PMID 25975659) supports uninterrupted rivaroxaban during ablation
7. dabigatran 150 mg BID (110 mg BID if age ≥75 or CrCl 30-50 in EU labelling) PO BID (DOAC_direct_thrombin, second line) — RE-CIRCUIT (PMID 28530171) — uninterrupted dabigatran non-inferior to interrupted during AF ablation
8. warfarin INR 2-3 PO daily (vitamin_K_antagonist, comorbidity specific) — Mechanical valve / severe MS — only warfarin — ACC/AHA 2024

Setting playbook (outpatient) — Long-term post-PVI / post-redo-ablation surveillance, lifelong AC (mixed AF/AFL substrate), AAD continuation if redo incomplete, recurrence + concomitant-AF screening — ACC/AHA 2024 (PMID 38753446)
9. continue DOAC lifelong if CHA2DS2-VASc ≥2 or mixed AF/AFL apixaban 5 mg BID per CHA2DS2-VASc PO BID — Persistent stroke risk OR mixed AF/AFL post-PVI (Lifelong AC — ACC/AHA 2024 Class I)
10. continue amiodarone if redo incomplete 200 mg PO daily PO daily — AAD-dependent rhythm maintenance (Lower recurrence than other AAD — ACC/AHA 2024)

Non-pharmacologic actions:
- Lifestyle: weight, alcohol limit, OSA treatment, exercise (ACC/AHA 2024)
- Vaccinations + secondary prevention bundle (ACC/AHA 2024)
- Annual EP review for repeat redo consideration if recurrence

AVOID / contraindication checks:
- Flecainide propafenone block if structural heart disease — CAST (PMID 1900101); ACC/AHA 2024 — post PVI substrate is inherently structural
- Dofetilide REMS inpatient initiation — ACC/AHA 2024 (PMID 38753446)
- Amiodarone monitor pulm thyroid LFT — ACC/AHA 2024
- Non DHP CCB block if EF lt 40 — ACC/AHA 2024
- LA redo ablation requires thrombus exclusion via TEE or CT if AC not uninterrupted 3wk — HRS 2017 (PMID 28506916)
- DOAC renal dose adjustment — ESC 2024 (PMID 39050851)
- NEVER interrupt AC without bridge during redo — RE CIRCUIT (PMID 28530171); VENTURE AF (PMID 25975659)

Monitoring

Regimen monitoring:
- telemetry continuous acute — ACC/AHA 2024
- HR target 80-110 pre redo ablation — ACC/AHA 2024
- QTc serial dofetilide sotalol amiodarone — ACC/AHA 2024
- PFTs TFTs LFTs baseline then q6m on amiodarone — ACC/AHA 2024
- lifelong AC due to mixed AF AFL coexistence post PVI — ACC/AHA 2024 Class I
- post-LA-redo-ablation atrioesophageal fistula warning ×6 weeks — HRS 2017 (PMID 28506916) — mitral isthmus line near esophagus
- post-LA-redo-ablation 4-week ECG + Holter 3-6-12 mo for AF AFL recurrence
- INR q week during warfarin initiation when used

Setting (outpatient) monitoring:
- Cardiology q3-6 mo first year then annually (ACC/AHA 2024)
- Holter at 3, 6, 12 mo post-redo (Calkins 2017)
- Annual TFTs / LFTs / PFTs on amiodarone (ACC/AHA 2024)
- CBC + eGFR q6m on DOAC (ESC 2024)

Follow-up plan: EP clinic at 4 weeks post-redo with 12-lead + Holter; AC continuation lifelong (mixed AF/AFL); lifestyle (alcohol, weight, OSA per LEGACY); 3, 6, 12-month Holter or wearable; counsel re: atrioesophageal fistula warning weeks 2-6 post-LA ablation
- Close-out criterion: Follow-up booked + redo ablation pathway entered

Monitoring phase: Telemetry; QTc on dofetilide / sotalol / amiodarone; post-redo-ablation observation for groin hematoma, tamponade, atrioesophageal fistula (LA mitral-isthmus line passes near esophagus — HIGHER RISK than CTI); AC adherence

Disposition

Current setting: outpatient — Long-term post-PVI / post-redo-ablation surveillance, lifelong AC (mixed AF/AFL substrate), AAD continuation if redo incomplete, recurrence + concomitant-AF screening — ACC/AHA 2024 (PMID 38753446)

Disposition criteria:
- Continue chronic surveillance with this engine; cross-link to cardio.afib.core.v1 if AF predominant

Escalation triggers (move to higher acuity):
- Recurrent post-PVI flutter despite redo → repeat 3D EP mapping (Calkins 2017)
- New AF detected → AF management via cardio.afib.core.v1; consider concurrent PVI completion at next ablation
- Amiodarone toxicity (pulm fibrosis, thyroid, LFT) → switch to dofetilide or repeat redo — ACC/AHA 2024
- Stroke / TIA on AC → workup + reassess regimen — ACC/AHA 2024

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Iatrogenic post-PVI atypical flutter with SBP <90, AMS, ongoing ischemia, or pulmonary edema → synchronized DCCV 100-200 J biphasic now (atypical may need higher energy than typical CTI)
- [LIFE_THREATENING] Fever + chest pain + new neurologic deficit 2-6 weeks post-LA redo (mitral isthmus line) → emergency surgical evaluation; HIGHER RISK than CTI
- [SEVERE] Periprocedural AC management for redo LA ablation — uninterrupted DOAC vs interrupted with bridge; RE-CIRCUIT and VENTURE-AF support uninterrupted

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); HRS/EHRA/ECAS/APHRS/SOLAECE 2017 expert consensus on AF catheter and surgical ablation (Calkins HeartRhythm 2017 PMID 28506916); ESC 2024 AF (Van Gelder PMID 39050851) [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 28506916) [PMID:28506916](https://pubmed.ncbi.nlm.nih.gov/28506916/)
- Cited evidence (PMID 18272844) [PMID:18272844](https://pubmed.ncbi.nlm.nih.gov/18272844/)
- Cited evidence (PMID 17698994) [PMID:17698994](https://pubmed.ncbi.nlm.nih.gov/17698994/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); HRS/EHRA/ECAS/APHRS/SOLAECE 2017 expert consensus on AF catheter and surgical ablation (Calkins HeartRhythm 2017 PMID 28506916); ESC 2024 AF (Van Gelder PMID 39050851) — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 28506916) — PMID:28506916
  • Cited evidence (PMID 18272844) — PMID:18272844
  • Cited evidence (PMID 17698994) — PMID:17698994